Skip to main content

Specialty Pharmacy

  • Diplomat to dispense Darzalex

    FLINT, Mich. — Diplomat Pharmacy will be dispensing Janssen’s Darzalex, the company announced Thursday. The drug will be dispensed in combination with Revlimid (lenalidomide) and dexamethasone or with Velcade (bortezomib) and dexamethasone. 
     
    The drug was approved by the Food and Drug Administration to treat multiple myeloma in patients who have received at least one other treatment. 
     

  • Amber pharmacy tops Zitter Health Insights survey in satisfaction

    OMAHA, Neb. — Employees of Hy-Vee’s specialty pharmacy subsidiary, Amber Pharmacy, came out on top of a recent patient satisfaction survey conducted by Zitter Health Insights. After asking some 3,000 patients at 38 American specialty pharmacies, Amber Health’s nurses, pharmacy technicians and billing department earned scores of 100% and their customer service representatives scored 95%. 
     

  • Report: Walgreens opens latest 'Community' specialty banner in Ohio market

  • J&J, Actelion Pharamceuticals confirm early talks for reported potential acquisition

    NEW BRUNSWICK, N.J. — On Nov. 25, Bloomberg reported that Johnson & Johnson and Actelion Pharmaceuticals were in discussion over a potential acquisition of Actelion by J&J. Both companies have confirmed that they are in preliminary discussions. 
     

  • Diplomat to dispense Cuvitru

    FLINT, Mich. — Diplomat Pharmacy announced Monday that it had begun filling prescriptions for Shire’s Cuvitru, which launched last week following its September approval by the Food and Drug Administration. The drug treats primary humoral immunodeficiency in patients ages 2 years and older. 
     
    "We are excited to offer patients a therapy that expands their options for treating primary immunodeficiency," Diplomat president Paul Urick said. "Cuvitru is an important treatment for patients with unmet needs."

  • Avella moves into new headquarters

    PHOENIX, Ariz. — Avella Specialty Pharmacy moved into its new 50,000-square-foot corporate headquarters here.

    According to Avella, the move allows the company to conduct its clinical, operational and administrative processes under one roof while maintaining greater scalability for future growth.

  • Survey: Doctors embrace biosimilars, but with caution

    BOSTON — A new survey from InCrowd is finding physicians more open to prescribing their patients biosimilars in the coming years, but they are also more cautious than they were six months ago about allowing pharmacy-level substitution. 
     

  • Allergan, Amgen submit application for possible Avastin biosimilar

    THOUSAND OAKS, Calif. — Amgen and Allergan on Wednesday announced their submission of a biologics license application to the Food and Drug Administration for ABP 215, a potential biosimilar of Avastin (bevacizumab). The companies said ABP 215 is the most advanced of the four oncologic biosimilars they are developing, and they believe it’s the first submission for an Avastin biosimilar. 
     
X
This ad will auto-close in 10 seconds